leisure time -WSS

leisure time

author：fashion 2025-09-06 02:15:14 - browse：373

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

WSS

U.K. researchers warn about biases in medical devices, algorithms

Biden tests positive for Covid

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Neuroscience’s long legacy of racism

Future doctors should be trained to promote social change

AI can’t replace a physician’s gut feeling

leisure time

leisure time

focus

Wildfire smoke exposes gaps in outdoor worker protections

Methadone treatment changes are coming. Do they go far enough?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In early work, researchers turn to CRISPR to treat Alzheimer's

In age of alternative facts, a scholarly course on calling out crap

Physicians and social media: If you see something, say something?

Medical records are filled with copy

AstraZeneca to buy developer of next

The high cost of giving birth even with insurance

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

leisure time

SCOTUS questions limit to govt efforts to fight misinformation

Health AI adoption puts security, privacy startups on investors' radar

In early work, researchers turn to CRISPR to treat Alzheimer's

Google and Epic fight stronger regulation of AI in health care

Gene editing the human germline: What are the risks?

SCOTUS questions limit to govt efforts to fight misinformation

entertainment

Wikipedia

focus

hotspot